NeoFipronis (Miaite) Package Insert and Dosage Information
NeoFipronis (Miaite), also known by its active ingredient Pronidesivir (GS-441524), is a groundbreaking oral treatment specifically designed for cats suffering from Feline Infectious Peritonitis (FIP). Approved by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026, NeoFipronis marks the first officially registered therapeutic agent for FIP in the world. Its innovative formulation offers a safe, non-invasive, and highly effective approach to combat this devastating disease.
FIP manifests with symptoms including anorexia, lethargy, fever, ascites, pleural effusion, lymphadenopathy, granulomatous inflammation, neural damage, and uveitis. The pathology involves a mutated gamma-coronavirus leading to systemic infection characterized by intense inflammation and organ damage. Traditional treatments have been limited, often leading to poor prognoses. NeoFipronis offers a promising solution with proven antiviral efficacy against feline coronavirus replication, significantly improving the survival rate and quality of life for affected cats.
The active compound, Pronidesivir, is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase. Extensive research and clinical trials have validated its potency in reducing viral load and ameliorating clinical symptoms. NeoFipronis's pharmacological profile demonstrates rapid absorption, ensuring quick onset of action. It is well-tolerated with minimal side effects, making it suitable for long-term therapy.
Dosing Instructions
The recommended dosage is calculated based on the cat's weight. Administer 15 mg per kilogram of body weight, approximately half a tablet per dose. For cats exhibiting neurological or ocular forms of FIP, the dosage should be increased to 30 mg/kg, under veterinary supervision. The medication is administered once daily, preferably on an empty stomach—either one hour before feeding or two hours after feeding—to maximize absorption.
Treatment Duration and Monitoring
NeoFipronis requires continuous administration for a minimum of 12 weeks to ensure complete viral clearance and prevent relapse. Consistent dosing without interruptions is crucial for treatment success. During therapy, owners should observe for changes in appetite, body temperature, and behavior. Regular veterinary evaluations, including blood tests and liver and kidney function assessments, are recommended to monitor the cat's response and detect any adverse effects early.
Precautions and Usage
Although NeoFipronis is available over the counter, veterinary guidance is highly advised to optimize treatment outcomes and minimize risks. The medication is strictly for feline use; human consumption is strictly prohibited. Overdose or improper use could lead to unforeseen complications.
Purchasing and Quality Assurance
To guarantee product authenticity and quality, NeoFipronis should be purchased exclusively through authorized channels. Visit the official NeoFipronis website for verified distributors and detailed product information.
Safety and Warnings
NeoFipronis, while generally safe, should be used with caution in cats with pre-existing health conditions. Discontinue use if adverse reactions occur and consult a veterinarian. Keep medication out of reach of children and pets.
Conclusion
NeoFipronis (Pronidesivir) stands as a major advancement in the fight against feline infectious peritonitis. With its proven efficacy, safety profile, and ease of administration, it has become a vital option for veterinarians and cat owners aiming to improve outcomes for cats battling FIP. Proper dosing, continuous treatment, and professional guidance are essential to maximize benefits and ensure the health and well-being of affected felines.
Note: Always consult a licensed veterinarian before initiating treatment with NeoFipronis.
